Monica Rodolfo

List of Publications by Year
in descending order

105 papers	5,258 citations	126858 33 h-index	88593 70 g-index
107 all docs	107 docs citations	107 times ranked	8917 citing authors

#	Article	IF	Citations
1	Extracellular vesicles in anti-tumor immunity. Seminars in Cancer Biology, 2022, 86, 64-79.	4.3	21
2	Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 213-221.	1.3	8
3	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. Journal of Investigative Dermatology, 2022, 142, 3030-3040.e5.	0.3	6
4	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
5	Identification of suitable mRNAs and microRNAs as reference genes for expression analyses in skin cells under sex hormone exposure. Gene, 2021, 769, 145336.	1.0	7
6	Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations. Cancers, 2021, 13, 2284.	1.7	13
7	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine, 2021, 11, e434.	1.7	3
8	Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients. Genes, 2021, 12, 1440.	1.0	2
9	Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist, 2021, 26, 1079-1084.	1.9	5
10	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Communication and Signaling, 2020, 18, 156.	2.7	18
11	microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1214.	2.2	12
12	Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk. Experimental Dermatology, 2020, 29, 980-986.	1.4	1
13	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	9.4	138
14	Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Cancer Research, 2020, 80, 2676-2688.	0.4	14
15	Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab.. Journal of Clinical Oncology, 2020, 38, 719-719.	0.8	1
16	Abstract 1899: Extracellular lipid starvation modulates the effects of BRAF inhibitors in melanoma. , 2020, , .		0
17	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
18	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16

#	Article	IF	Citations
19	Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk. Melanoma Research, 2019, 29, 660-663.	0.6	10
20	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 407-420.	1.4	39
21	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. Annals of the Rheumatic Diseases, 2019, 78, 862-864.	0.5	8
22	The ACC melanoma pilot project: â€œReal-worldâ€•evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	0.8	0
23	miR-100 and miR-125b regulate epithelial-mesenchymal transition and drug resistance in tumors. Non-coding RNA Investigation, 2018, 2, 57-57.	0.6	5
24	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Human Molecular Genetics, 2018, 27, 4145-4156.	1.4	34
25	MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2134-2141.	1.3	9
26	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Journal of Clinical Investigation, 2018, 128, 5505-5516.	3.9	193
27	Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphismsâ€™ interaction as a susceptibility factor for melanoma skin cancer. Melanoma Research, 2017, 27, 309-314.	0.6	13
28	Melanoma risk alleles are associated with downregulation of the <scp>MTAP</scp> gene and hypermethylation of a CpG island upstream of the gene in dermal fibroblasts. Experimental Dermatology, 2017, 26, 733-736.	1.4	3
29	Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients. Journal of Investigative Dermatology, 2017, 137, 766-768.	0.3	4
30	Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response (LTR) to vemurafenib (Vb).. Journal of Clinical Oncology, 2017, 35, e21001-e21001.	0.8	0
31	Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines, 2016, 4, 38.	2.1	20
32	microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes, 2016, 7, 124.	1.0	8
33	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332.	0.6	32
34	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget, 2016, 7, 4428-4441.	0.8	84
35	Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma<i>in vivo</i>. Oncotarget, 2016, 7, 12857-12868.	0.8	32
36	ITOC2 â€“ 038. Role of exosomes in immune suppression. European Journal of Cancer, 2015, 51, S13.	1.3	3

#	Article	IF	Citations
37	Association of micro<scp>RNA</scp> 146a polymorphism rs2910164 and the risk of melanoma in an Italian population. Experimental Dermatology, 2015, 24, 794-795.	1.4	8
38	Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunology, Immunotherapy, 2015, 64, 83-89.	2.0	17
39	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget, 2014, 5, 4516-4528.	0.8	29
40	Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Review of Molecular Diagnostics, 2014, 14, 643-646.	1.5	23
41	Immune response markers in sentinel nodes may predict melanoma progression. OncoImmunology, 2014, 3, e28498.	2.1	6
42	Association of promoter polymorphism âˆ’765<scp>G</scp>><scp>C</scp> in the <scp>PTGS</scp>2 gene with malignant melanoma in <scp>I</scp>talian patients and its correlation to gene expression in dermal fibroblasts. Experimental Dermatology, 2014, 23, 766-768.	1.4	4
43	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. Cancer Research, 2014, 74, 130-140.	0.4	27
44	Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. Journal of Investigative Dermatology, 2014, 134, 1893-1902.	0.3	74
45	A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. BMC Medical Genetics, 2014, 15, 59.	2.1	18
46	Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of <i><scp>MITF</scp>,<scp> PTEN</scp></i> and <i><scp>CDKN</scp>2A</i> in multiple cancerogenesis?. Pigment Cell and Melanoma Research, 2013, 26, 755-757.	1.5	3
47	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	9.4	111
48	<scp>CDKN</scp>2A and <scp>MC</scp>1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. Experimental Dermatology, 2013, 22, 411-416.	1.4	26
49	Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis, 2012, 33, 781-790.	1.3	13
50	Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032. Neoplasia, 2011, 13, 1132-IN17.	2.3	89
51	BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients. , 2011, , .		1
52	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	2.3	237
53	MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. Journal of Investigative Dermatology, 2010, 130, 2062-2070.	0.3	204
54	Response to Griewank and Bastian. Journal of Investigative Dermatology, 2010, 130, 2331-2332.	0.3	0

#	Article	IF	Citations
55	CCN3 Promotes Melanoma Progression by Regulating Integrin Expression, Adhesion and Apoptosis Induced by Cytotoxic Drugs. , 2010, , 205-211.		0
56	Mutational Profile of GNAQQ209 in Human Tumors. PLoS ONE, 2009, 4, e6833.	1.1	63
57	Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix. Cell Adhesion and Migration, 2009, 3, 7-10.	1.1	12
58	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Human Mutation, 2009, 30, E451-E459.	1.1	41
59	<i>IDH1</i>mutations at residue p.R132 (IDH1^{R132}) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation, 2009, 30, 7-11.	1.1	348
60	Molecular profiling of the Ã¢Â€ÂœplexinomeÃ¢Â€Â•in melanoma and pancreatic cancer. Human Mutation, 2009, 30, 1167-1174.	1.1	40
61	Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. Journal of Investigative Dermatology, 2009, 129, 1759-1768.	0.3	54
62	New common variants affecting susceptibility to basal cell carcinoma. Nature Genetics, 2009, 41, 909-914.	9.4	303
63	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	0.6	45
64	High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene, 2008, 27, 1834-1843.	2.6	40
65	AKT1E17K in human solid tumours. Oncogene, 2008, 27, 5648-5650.	2.6	181
66	Prosurvival Effect of DHCR24/Seladin-1 in Acute and Chronic Responses to Oxidative Stress. Molecular and Cellular Biology, 2008, 28, 539-550.	1.1	77
67	CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma. Cancer Research, 2008, 68, 715-723.	0.4	64
68	<i>RNASET2</i> as a Tumor Antagonizing Gene in a Melanoma Cancer Model. Oncology Research, 2008, 17, 69-74.	0.6	35
69	Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma. Cancer Research, 2007, 67, 3545-3550.	0.4	153
70	Detection of mutated BRAFV600E variant in circulating DNA of stage IIIâ€"IV melanoma patients. International Journal of Cancer, 2007, 120, 2439-2444.	2.3	76
71	MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11160-11165.	3.3	221
72	A Merging Duo in Melanoma Formation. Journal of Investigative Dermatology, 2005, 125, xii-xiii.	0.3	2

#	Article	IF	Citations
73	DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. International Journal of Cancer, 2005, 115, 224-230.	2.3	72
74	CTAB-Urea Method Purifies RNA from Melanin for cDNA Microarray Analysis. Pigment Cell & Melanoma Research, 2004, 17, 312-315.	4.0	26
75	BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene, 2004, 23, 5968-5977.	2.6	189
76	Genetic progression of metastatic melanoma. Cancer Letters, 2004, 214, 133-147.	3.2	62
77	Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice. Journal of Immunology, 2002, 169, 151-158.	0.4	34
78	Prevention of spontaneous mammary adenocarcinoma in HERâ€2/neu transgenic mice by foreign DNA. FASEB Journal, 2002, 16, 1749-1754.	0.2	30
79	CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. British Journal of Cancer, 2001, 85, 836-844.	2.9	55
80	Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Therapy, 2001, 8, 491-496.	2.2	20
81	Immunizing Potential of Cytokine-Transduced Tumor Cells. , 2000, 35, 3-26.		0
82	Immunological Gene Therapy withex VivoGene-Modified Tumor Cells: A Critique and a Reappraisal. Human Gene Therapy, 2000, 11, 1269-1275.	1.4	57
83	Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response. Journal of Experimental Medicine, 1999, 190, 125-134.	4.2	168
84	Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Therapy, 1999, 6, 865-872.	2.3	21
85	Interleukin-12 as an Adjuvant for Cancer Immunotherapy. Methods, 1999, 19, 114-120.	1.9	60
86	Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.. Journal of Experimental Medicine, 1996, 183, 317-322.	4.2	516
87	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials?. Cancer Immunology, Immunotherapy, 1995, 41, 265-270.	2.0	20
88	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?. Cancer Immunology, Immunotherapy, 1995, 41, 265-270.	2.0	2
89	Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. International Journal of Cancer, 1994, 57, 440-447.	2.3	14
90	Heterogeneity and Phenotypic Instability of Chemotherapeutic and Immunologic Sensitivity in Murine and Human Melanoma Cell Clones. Tumori, 1992, 78, 5-9.	0.6	4

#	Article	IF	Citations
91	Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour. Cancer Immunology, Immunotherapy, 1992, 34, 383-388.	2.0	4
92	Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.. Journal of Experimental Medicine, 1991, 173, 889-897.	4.2	304
93	Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. British Journal of Haematology, 1991, 78, 197-205.	1.2	24
94	Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours. Cancer Immunology, Immunotherapy, 1991, 34, 53-62.	2.0	15
95	Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Cancer Immunology, Immunotherapy, 1990, 31, 28-36.	2.0	13
96	Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors. Cancer Immunology, Immunotherapy, 1990, 31, 37-43.	2.0	6
97	Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. European Journal of Cancer & Clinical Oncology, 1990, 26, 1079-1083.	0.9	29
98	High incidence of chromosomal lesions involving C-heterochromatin in four human melanoma lines. Clinical and Experimental Metastasis, 1989, 7, 633-644.	1.7	5
99	Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs. Cancer Immunology, Immunotherapy, 1989, 28, 136-42.	2.0	10
100	Growth Inhibition of Murine Colonic Adenocarcinoma by Tumor Immune but not by IL-2-Activated or Alloactivated Lymphocytes. Tumori, 1987, 73, 1-9.	0.6	5
101	Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. Biochimica Et Biophysica Acta: Reviews on Cancer, 1987, 907, 163-174.	3.3	3
102	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
103	Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype. Tumori, 1985, 71, 91-96.	0.6	0
104	H-2K RESTRICTION OF THE T CELL-MEDIATED LYSIS OF A CHEMICALLY-INDUCED BALB/c FIBROSARCOMA. International Journal of Immunogenetics, 1983, 10, 337-340.	1.2	2
105	Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	10